Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Rev. bras. epidemiol ; 20(3): 526-536, Jul.-Set. 2017. tab
Article in Portuguese | LILACS | ID: biblio-898606

ABSTRACT

RESUMO: Introdução: A síndrome da lipodistrofia do HIV é caracterizada por alterações no metabolismo e na composição corporal, que aumentam o risco cardiovascular de pessoas vivendo com HIV/AIDS (PVHA) em uso da terapia antirretroviral de alta potência (TARV). Objetivo: Avaliar a prevalência de lipodistrofia e de alterações do metabolismo de lipídios e glicose em PVHA em uso da TARV. Métodos: Para avaliação antropométrica foram aferidos peso, estatura e circunferência abdominal (CA). Para avaliação da lipodistrofia foi realizado o exame físico (subjetivo) e o exame (objetivo) de absortometria com raios X de dupla energia (DEXA) por meio da razão de massa gorda (RMG). Foram também realizados exames de lipidograma e glicemia de jejum e utilizados os critérios sugeridos pelo The National Cholesterol Education Program III para classificação de alterações metabólicas. Resultados: A amostra final consistiu em 262 pacientes com idade média de 44,3 ± 10,2 anos. A lipodistrofia, de acordo com o exame físico, esteve presente em 47,7% (IC95% 41,7 - 53,8) dos pacientes, enquanto pela RMG (DEXA) sua prevalência foi de 40,8% (IC95% 33,1 - 48,5). A maioria (53,0%; IC95% 47,0 - 59,1) dos pacientes apresentou aumento de adiposidade abdominal segundo a CA. As alterações metabólicas mais presentes foram o HDL reduzido (67,6%; IC95% 61,9 - 73,2) e a hipertrigliceridemia (55,7%; IC95% 49,7 - 61,7). Conclusões: A alta prevalência de lipodistrofia e alterações do metabolismo de lipídios e glicose evidenciam a importância da intervenção precoce nesse grupo de pacientes para prevenir complicações cardiovasculares.


ABSTRACT: Introduction: The HIV lipodystrophy syndrome is characterized by changes in metabolism, and body composition that increase cardiovascular risk of people living with HIV/AIDS (PLWHA) using highly active antiretroviral therapy (HAART). Objective: To assess the prevalence of lipodystrophy and changes in lipid and glucose metabolism in PLWHA in use of HAART. Methods: For the anthropometric evaluation we measured weight, height and abdominal circumference (AC). For the lipodystrophy evaluation we conducted physical examination (subjective) and the (objective) examination of absorptiometry with X-ray dual energy (DEXA) by fat mass ratio (FMR). We also conducted lipid profile tests and fasting glucose and used the criteria suggested by The National Cholesterol Education Program III for metabolic disorders classification. Results: The final sample consisted of 262 patients with a mean age of 44.3 ± 10.2 years. Lipodystrophy, according to the physical examination, was present in 47.7% (95%CI 41.7 - 53.8) of patients, while the prevalence using FMR (DEXA) was 40.8% (95%CI 33.1 - 48.5). Most (53.0%; 95%CI 47.0 - 59.1) of the patients showed increased abdominal adiposity according to AC. The most prevalent metabolic alterations were reduced HDL (67.6%; 95%CI 61.9 - 73.2) and hypertriglyceridemia (55.7%; 95%CI 49.7 - 61.7). Conclusion: The high prevalence of lipodystrophy and changes in lipid and glucose metabolism show the importance of early intervention in this group of patients to prevent cardiovascular complications.


Subject(s)
Humans , Male , Female , Adult , HIV Infections/metabolism , HIV Infections/drug therapy , Adipose Tissue , Antiretroviral Therapy, Highly Active , Lipid Metabolism , Glucose/metabolism , Lipodystrophy/epidemiology , HIV Infections/complications , Prevalence , Cross-Sectional Studies , Acquired Immunodeficiency Syndrome/metabolism , Lipodystrophy/etiology
2.
Rev. cuba. enferm ; 31(1): 0-0, ene.-mar. 2015. ilus
Article in Spanish | LILACS, CUMED, BDENF | ID: lil-797676

ABSTRACT

Introducción: la Diabetes Mellitus tipo 1 se encuentra entre las enfermedades crónicas más frecuentes de la infancia. El diagnóstico de diabetes puede provocar un impacto emocional importante para la familia y el paciente, que una vez diagnosticado necesita administración de insulina de por vida, provocando a largo plazo lesiones en los sitios de inyección. Objetivo: identificar la Incidencia de lipodistrofia insulínica en niños y adolescentes diabéticos tipo 1. Métodos: estudio descriptivo de corte transversal con 60 diabéticos tipo 1, de cinco a 18 años de edad, atendidos en el Hospital Pediátrico de Centro Habana durante 2013. Se realizó examen físico mediante observación y palpación del sitio de inyección para identificar lipodistrofia, se aplicó una encuesta para evaluar los conocimientos y habilidades en la técnica de administración de insulina. Se calculó el índice de incidencia de lipodistrofia, los resultados se expresaron en porcentajes. Resultados: se encontró lipodistrofia insulínica en el 70 por ciento de los pacientes, el 35 por ciento tenía lesiones en dos zonas, el 30 por ciento en una zona y el 5 por ciento en tres regiones, los brazos fueron la región más frecuente; seguida del abdomen, muslos y glúteos. El 83,33 por ciento de los pacientes presentó deficiencias en conocimientos y habilidades del tratamiento insulínico. Conclusiones: en los pacientes estudiados existe alta incidencia de lipodistrofia insulínica, no asociada al tipo de insulina administrada, se encontró deficiencias en conocimientos y aplicación del tratamiento insulínico(AU)


Introduction: Type 1 diabetes mellitus is among the most frequent chronic diseases at childhood. The diagnosis may cause a significant emotional impact on the family and the patient as well, and once diagnosed, this patient will need life-long insulin administration that will lead to long-term injures in the injection sites. Objective: To identify the incidence of insulin lipodystrophy in type 1 diabetes children and adolescents. Methods: Cross-sectional descriptive study performed in 60 type 1 diabetes children aged 1 to 18 years and seen at the pediatric hospital of Centro Habana in 2013. They were physically examined through observation and palpation of the injection site in order to detect lipodystrophy. A survey was also made to evaluate knowledge and skills in administering insulin. The incidence rate of lipodystrophy was estimated and the results were given in percentages. Results: There was insulin lipodystrophy in 70 percent of patients; 35 percent had lesions in two areas; 30 percent in one area and 5 percent in three area; the arms was the most used area followed by abdomen, thighs and buttocks. In this group, 83.33 percent of patients showed deficient knowledge and skills regarding the insulin treatment. Conclusions: Insulin lipodystrophy incidence is high in the studied patients, unrelated to the type of administered insulin; there was poor knowledge and deficiencies in applying the insulin treatment correctly(AU)


Subject(s)
Humans , Child , Adolescent , Diabetes Mellitus, Type 1/diagnosis , Insulin/administration & dosage , Lipodystrophy/epidemiology , Epidemiology, Descriptive , Cross-Sectional Studies
3.
Cienc. Trab ; 15(47): 81-85, ago. 2013. ilus, tab
Article in Spanish | LILACS | ID: lil-700423

ABSTRACT

La Lipoatrofia Semicircular (LS) es una enfermedad idiopática, que se caracteriza por una atrofia reversible y localizada, ya sea total o parcial, del tejido adiposo subcutáneo y que se ubica en zonas de contacto de la piel de las extremidades con el inmobiliario. Se caracteriza por presentarse en brotes endémicos, cuyo único factor en común es el lugar de trabajo. Sus causas son desconocidas, pero en la actualidad se proponen factores asociados como: el contacto de la zona afectada con inmobiliario, presencia de radiación electromagnética, presencia de descargas electroestáticas y humedad ambiental relativa baja. Un modelo actual para explicar la patogenia de esta enfermedad involucra la participación de descargas electrostáticas, que probablemente activarían la liberación de factor de necrosis tumoral a (TNF-a) y desencadenaría la fagocitosis de adipocitos. Actualmente no tiene un tratamiento médico, siendo las medidas preventivas de mitigación de los factores previamente mencionados las que producen una reversión de la lesión. Por otro lado, la presencia de estos brotes generan un gran impacto mediático por lo que también debe ser abordada comunicacionalmente. La presente revisión pretende sintetizar la literatura sobre el tema para exponer el conocimiento actual y lograr una noción de esta nueva enfermedad, tras su primera presentación en brote en nuestro país.


Lipoatrophia semicircularis (LS) (also known as "Semicircular lipoa-trophy") is an idiopathic disease, which is characterized by a reversible and localized atrophy, either total or partial, of subcutaneous adipose tissue and located in areas of skin contact with the real estate tips. It is characterized by appearing in endemic outbreaks whose only common factor is the workplace. Its causes are unknown, but currently associated factors have been proposed, such as: the contact area with the office furniture, the presence of electromagnetic radiation, electrostatic discharge and presence of low relative humidity. A current model to explain the pathogenesis of this disease involves the participation of electrostatic discharges, which probably activate the release of tumor necrosis factor a (TNF-a) and it would trigger phagocytosis of adipocytes. Currently there is no medical treatment, being proactive mitigation measures of the before mentioned factors, those that produce a reversion of the injury. On the other hand, the presence of these buds generates great media impact so it must be also addressed from a communication standpoint. The present review aims to summarize the literature on the subject to present current knowledge and achieve a notion of this new disease, after its first appearance in outbreak in our country.


Subject(s)
Humans , Lipodystrophy/diagnosis , Lipodystrophy/epidemiology , Occupational Diseases/diagnosis , Occupational Diseases/epidemiology , Risk Management , Chile , Disease Outbreaks , Workplace , Static Electricity/adverse effects , Electromagnetic Radiation , Lipodystrophy/etiology , Lipodystrophy/prevention & control , Occupational Diseases/etiology , Occupational Diseases/prevention & control
4.
Rev. Assoc. Med. Bras. (1992) ; 58(1): 70-75, jan.-fev. 2012. tab
Article in English | LILACS | ID: lil-617111

ABSTRACT

OBJECTIVE: Prevalence of chronic complications of HIV infection is increasing and early recognition and treatment of the components of metabolic syndrome (MS) are essential to prevent cardiovascular and metabolic complications. Considering this, we performed a cross-sectional study on the prevalence and risk-factors for MS among HIV-infected subjects. METHODS: A total of 819 patients followed at a large outpatient HIV unit were assessed by an interviewer-administered questionnaire that recorded several demographic, epidemiologic, clinical, laboratory, and social variables. Lipodystrophy diagnosis relied on agreement between patient's self-report and physician's observation of altered body-fat deposits. The presence of three or more of the following characteristics identified MS: increased waist circumference, hypertriglyceridemia, low HDL cholesterol level, hypertension, and hyperglycemia. We used logistic regression analyses to study variables independently associated with MS. RESULTS: The prevalence of MS was 20.6 percent and that of lipodystrophy was 38.5 percent. 61 (36.1 percent) out of 169 patients with MS had also lipodystrophy. Patients with metabolic syndrome were significantly more likely to be older (OR = 1.08), had higher CD4 counts (OR = 1.001), had an increased body mass index (OR = 1.27) and had longer exposure to antiretroviral therapy (OR = 1.01) than those without metabolic syndrome. CONCLUSION: Both traditional risk factors for cardiovascular disease and factors associated with HIV infection itself, such as an increased CD4 cell count and a longer exposure to antiretroviral therapy, seem to be associated with metabolic syndrome in the present study population.


OBJETIVO: A prevalência de complicações crônicas da infecção HIV está aumentando, e o reconhecimento precoce e o tratamento dos componentes da síndrome metabólica (SM) são essenciais para a prevenção de complicações cardiovasculares e metabólicas. Considerando isso, realizamos um estudo transversal sobre prevalência e fatores de risco para SM em indivíduos HIV+. MÉTODOS: Um total de 819 pacientes acompanhados em um ambulatório de HIV foi avaliado por um entrevistador que registrou em questionário dados demográficos, epidemiológicos, clínicos, laboratoriais e variáveis sociais. O diagnóstico de lipodistrofia baseou-se na concordância entre autorrelato do paciente e observação do médico das alterações de gordura corporal. A SM foi identificada pela presença de três ou mais das seguintes características: circunferência abdominal aumentada, hipertrigliceridemia, colesterol HDL baixo, hipertensão e hiperglicemia. Análises de regressão logística foram utilizadas para identificar variáveis associadas à SM. RESULTADOS: A prevalência de SM foi 20,6 por cento e de lipodistrofia foi 38,5 por cento. Entre os 169 pacientes com SM, 61 (36,1 por cento) apresentavam lipodistrofia. Os pacientes com síndrome metabólica tinham, significativamente, maior probabilidade de ser mais velhos (OR = 1,08), ter maior contagem de CD4 (OR = 1,001), ter maior índice de massa corporal (OR = 1,27) e ter maior tempo de exposição à terapia antirretroviral (OR = 1,01). CONCLUSÃO: Tanto fatores de risco tradicionais para doença cardiovascular quanto fatores associados à infecção HIV, como aumento da contagem de CD4 e maior exposição à terapia antirretroviral, parecem estar associados à SM na população estudada.


Subject(s)
Adolescent , Adult , Aged , Female , Humans , Male , Middle Aged , Young Adult , HIV Infections/complications , HIV-Associated Lipodystrophy Syndrome/epidemiology , Lipodystrophy/epidemiology , Metabolic Syndrome/epidemiology , Anti-HIV Agents/adverse effects , Antiretroviral Therapy, Highly Active/adverse effects , Cross-Sectional Studies , HIV Infections/drug therapy , HIV-Associated Lipodystrophy Syndrome/chemically induced , Lipodystrophy/chemically induced , Metabolic Syndrome/complications , Prevalence , Risk Factors
5.
Rev. chil. dermatol ; 28(1): 32-34, 2012.
Article in Spanish | LILACS | ID: lil-718670

ABSTRACT

La celulitis es una entidad que afecta a la mayoría de las mujeres. Existen varias teorías sobre su fisiopatología. Sabemos que la hormona tiroidea tiene un efecto a nivel cutáneo, y en nuestro país se ha reportado una mayor prevalencia de hipotiroidismo que en otros países. Objetivo: Comparar la prevalencia de hipotiroidismo en mujeres que consultaron para tratamiento de celulitis y/o flaccidez abdominal en un centro dermatológico de Santiago con la reportada en la literatura. Materiales y métodos: Se realizó un estudio retrospectivo con 122 pacientes evaluadas entre noviembre 2009 y enero 2012. Se excluyeron 25 por no contar con anamnesis completa. Los datos fueron obtenidos de la entrevista inicial, y de la ficha clínica cuando ésta estaba incompleta. Resultados: Se obtuvo una prevalencia de 19 por ciento, valor significativamente mayor (p<0,001)a la reportada en la literatura (6,8 por ciento en Chile y entre 5 por ciento y 10 por ciento en otros países).


Cellulite is an entity that affects most women. There are many theories about its physiopathology. It is known that the thyroid hormone has an effect on the skin, and there are reports of a higher prevalence of hypothyroidism in our country than elsewhere. Objective: Compare the prevalence of hypothyroidism in women who consulted for cellulite and/or abdominal flabbiness in a dermatologic clinic in Santiago, with the data reported in the literature. Materials and methods: We performed a retrospective study with 122 patients who consulted between November 2009 and January 2012, of whom 25 were excluded because of incomplete data. Information was obtained from the initial interview, and, if missing some data, from the clinical records. Results: We found a prevalence of 19 percent, which is significantly higher (p<0,001) than the value reported in the literature (6,8 percent in Chile, and between 5 percent and 10 percent elsewhere).


Subject(s)
Humans , Adult , Female , Middle Aged , Aged, 80 and over , Hypothyroidism/epidemiology , Lipodystrophy/epidemiology , Chile , Prevalence , Retrospective Studies
6.
Braz. j. med. biol. res ; 44(11): 1177-1183, Nov. 2011. tab
Article in English | LILACS | ID: lil-604282

ABSTRACT

The aim of this study was to determine the impact of antiretroviral therapy on the lipid profile of human immunodeficiency virus (HIV) patients before and after the initiation of highly active antiretroviral therapy (HAART). This was a cross-sectional analysis of patients receiving HAART at a reference center in Belo Horizonte, Brazil, on the basis of medical records from 2002 to 2006. Patients were included if they had at least one lipid test or a clinical or laboratory diagnosis of dyslipidemia/lipodystrophy. Among the 692 patients, 620 met the eligibility criteria. The majority were males (66.5 percent), middle age (average 39 years), had a low educational level (60.4 percent), and low income (51.0 percent). HAART duration ranged from 11 days to 4.6 years, with a mean of 28.6 months (SD = ± 470.19 days). The prevalence of dyslipidemia/lipodystrophy nearly tripled (11.3 percent pre- and 32.4 percent post-HAART). Dyslipidemia was associated with older age (P = 0.007), nucleoside reverse transcriptase inhibitor (NRTI) + protease inhibitor (PI) regimens (P = 0.04), NRTI + non-NRTI (NNRTI) regimens (P = 0.026), the use of stavudine (d4T) in any regimen (P = 0.002) or in NRTI-based regimens (P = 0.006), and longer exposure to HAART (P < 0.000). In addition, there was no correlation between dyslipidemia and gender (P = 0.084). Only 2.0 percent of the patients received treatment for dyslipidemia during the trial. These results show a need for continuous monitoring of patients under antiretroviral therapy, particularly those using NRTI-based regimens, especially when combined with d4T and PIs. Secondly, interventions should be developed to correct metabolic changes.


Subject(s)
Adolescent , Adult , Aged , Female , Humans , Male , Middle Aged , Young Adult , Dyslipidemias/epidemiology , HIV Infections/drug therapy , HIV Protease Inhibitors/adverse effects , Lipodystrophy/epidemiology , Reverse Transcriptase Inhibitors/adverse effects , Stavudine/adverse effects , Antiretroviral Therapy, Highly Active/adverse effects , Brazil/epidemiology , Cross-Sectional Studies , Drug Therapy, Combination/adverse effects , Dyslipidemias/chemically induced , Lipodystrophy/chemically induced , Statistics, Nonparametric , Treatment Outcome
7.
Arq. bras. cardiol ; 95(5): 640-647, out. 2010. ilus, graf, tab
Article in Portuguese | LILACS | ID: lil-570440

ABSTRACT

FUNDAMENTO: Hipertensão arterial sistêmica (HAS) é fator de risco modificável, cujo controle pode reduzir doença cardiovascular nos pacientes com vírus da imunodeficiência adquirida (HIV). OBJETIVO: Estimar a prevalência de HAS e descrever as características dos pacientes com HAS e pré-hipertensão infectados pelo HIV/AIDS. MÉTODOS: Estudo seccional alinhado a uma coorte de pacientes com HIV/AIDS. Considerou-se hipertensão em níveis > 140/90 mmHg ou uso de anti-hipertensivos e pré-hipertensão em níveis > 120/80 mmHg. RESULTADOS: Dos 958 pacientes, 388 (40,5 por cento) eram normotensos, 325 (33,9 por cento) pré-hipertensos e 245 (25,6 por cento) hipertensos. Desses 245 pacientes, 172 (70,2 por cento) sabiam ser hipertensos e 36 (14,8 por cento) apresentavam pressão arterial controlada. Tiveram diagnóstico de HAS após o diagnóstico do HIV 62 pacientes (54,4 por cento). Lipodistrofia ocorreu em 95 (46,1 por cento) dos pacientes, já sobrepeso/obesidade em 129 (52,7 por cento). Utilização de antirretrovirais ocorreu em 184 (85,9 por cento), 89 (41,6 por cento) com inibidores de protease (IP) e 95 (44,4 por cento) sem IP. Utilizavam antivirais > 24 meses 74,7 por cento. Idade, antecedentes familiares de hipertensão, circunferência abdominal, índice de massa corporal e triglicerídeos foram maiores entre pacientes hipertensos. Tempo de infecção pelo HIV, contagem de linfócitos CD4, carga viral, tempo e tipo de esquema antirretroviral foram semelhantes nos hipertensos e pré-hipertensos. CONCLUSÃO: A elevada frequência de hipertensos não controlados e de riscos cardiovasculares nos infectados pelo HIV apontam a necessidade de medidas preventivas e terapêuticas contra HAS nesse grupo.


BACKGROUND: Hypertension (HBP) is modifiable risk factor, whose control may reduce cardiovascular disease in patients with human immunodeficiency virus (HIV). OBJECTIVE: To estimate the prevalence of hypertension and describe the characteristics of patients with hypertension infected by HIV/AIDS. METHODS: A cross-sectional study aligned to a cohort of patients with HIV/AIDS. The study considered hypertension at levels > 140/90 mmHg or use of antihypertensive drugs and pre-hypertension at levels > 120/80 mmHg. RESULTS: Out of 958 patients, 388 (40.5 percent) were normotensive, 325 (33.9 percent) were pre-hypertensive, and 245 (25.6 percent) were hypertensive. Out of these 245 patients, 172 (70.2 percent) were aware of the fact there they were hypertensive, and 36 (14.8 percent) had blood pressure controlled. Sixty-two (62) patients (54.4 percent) were diagnosed with hypertension after HIV diagnosis. Lipodystrophy occurred in 95 (46.1 percent) patients; overweight/obesity in 129 (52.7 percent). Use of antiretrovirals occurred in 184 (85.9 percent), 89 (41.6 percent) with protease inhibitors (PI) and 95 (44.4 percent) without PI. Out of these patients, 74.7 used antivirals > 24 months. Age, family history of hypertension, waist circumference, body mass index and triglyceride levels were higher among hypertensive patients. Time of HIV infection, CD4 count, viral load, time and type of antiretroviral regimen were similar in hypertensive and prehypertensive patients. CONCLUSION: The high frequency of uncontrolled hypertensive patients and cardiovascular risks in HIV-infected patients point out to the need for preventive and therapeutic measures against hypertension in this group.


Subject(s)
Adult , Female , Humans , Male , Acquired Immunodeficiency Syndrome/epidemiology , Hypertension/epidemiology , Life Style , Acquired Immunodeficiency Syndrome/drug therapy , Anti-HIV Agents/therapeutic use , Body Mass Index , Brazil/epidemiology , Chi-Square Distribution , Cohort Studies , Cross-Sectional Studies , Hypertension/classification , Lipodystrophy/epidemiology , Obesity/epidemiology , Reference Values , Risk Factors
8.
Article in English | IMSEAR | ID: sea-41705

ABSTRACT

BACKGROUND: Previous cross sectional studies revealed that dyslipidemia occurs in 50-70% of children receiving highly active antiretroviral therapy (HAART). However, there is no information in children in developing countries where children may have a different nutritional status. OBJECTIVE: To evaluate the incidence and associated risk factors of dyslipidemia following HAART in HIV-infected Thai children. The occurrence of clinical lipodystrophy among these children was also evaluated. MATERIAL AND METHOD: Twenty-three HIV-infected children who initiated HAART from "Access to Care Program" sponsored by MOPH around October 2001. Non-fasting blood tests for lipid profile were performed at enrollment and every 6 months. Triglyceride level was not analysed due to a non-fasting condition. The assessment of clinical lipodystrophy was done every 1-2 months. RESULTS. As of October 2003, 19 (83%) children experienced dyslipidemia. There were 10, 13, 5, and 8 children who had dyslipidemia at 6, 12, 18, and 24 months of HAART The mean total cholesterol, low density lipoprotein (LDL), and high density lipoprotein (HDL) tended to increase over time while the children were on HAART: There was a correlation of elevated total cholesterol and CD4 percentage gain particularly at 18-24 months of treatment (r = 0.596, p = 0.007). Two children developed peripheral lipoatrophy. There were no dyslipidemia-associated risk factors identified. Most of the children had transient abnormal lipid profile. There were only 3 children that had persistent abnormality throughout the 24 months of HAART CONCLUSION: Dyslipidemia was found from 6-12 months of HAART and were mostly transient over time. Peripheral lipoatrophy were found in 2 children. Further follow-up will elucidate the long-term incidence, the association factors, and clinical consequences.


Subject(s)
Antiretroviral Therapy, Highly Active , Child , Child, Preschool , Cross-Sectional Studies , Dyslipidemias/epidemiology , Female , HIV Infections/drug therapy , Humans , Incidence , Infant , Lipodystrophy/epidemiology , Longitudinal Studies , Male , Prospective Studies , Risk Factors , Thailand/epidemiology
9.
Indian J Med Sci ; 1970 Mar; 24(3): 149-51
Article in English | IMSEAR | ID: sea-68631
SELECTION OF CITATIONS
SEARCH DETAIL